var data={"title":"Pilocarpine (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pilocarpine (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390319?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pilocarpine-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pilocarpine (systemic): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24521000\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Salagen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505051\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Salagen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9509745\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Cholinergic Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505214\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Xerostomia:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Associated with head and neck cancer:</i> Initial: 5 mg 3 times daily; may titrate dose based on response and tolerability; usual dosage range: 15 to 30 mg/day; maximum: 10 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Sj&ouml;gren syndrome:</i> 5 mg 4 times daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505215\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370241\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505216\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment (Child-Pugh score 5 to 6): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate impairment (Child-Pugh score 7 to 9): Initial: 5 mg twice daily; adjust dose based on response and tolerability.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (Child-Pugh score 10 to 15): Use is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505264\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Salagen: 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Salagen: 7.5 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 7.5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505053\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505218\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid administering with high-fat meal. Ensure adequate water intake (dehydration may develop with use).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505054\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Xerostomia: </b> Treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; treatment of symptoms of dry mouth in patients with Sj&ouml;gren syndrome.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505046\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Salagen may be confused with selegiline</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505074\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Flushing (8% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Chills (3% to 15%), dizziness (5% to 12%), headache (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (6% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Urinary frequency (9% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (2% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Rhinitis (5% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Diaphoresis (29% to 68%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Edema (&lt;1% to 5%), facial edema, hypertension (3%), palpitation, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Pain (4%), fever, somnolence</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Pruritus, rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Diarrhea (4% to 7%), dyspepsia (7%), vomiting (3% to 4%), constipation, flatulence, glossitis, salivation increased, stomatitis, taste perversion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Vaginitis, urinary incontinence</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Myalgias, tremor</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ocular: Lacrimation (6%), amblyopia (4%), abnormal vision, blurred vision, conjunctivitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Cough increased, dysphagia, epistaxis, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Allergic reaction, voice alteration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%: Abnormal dreams, abnormal thinking, alopecia, angina pectoris, anorexia, anxiety, aphasia, appetite increased, arrhythmia, arthralgia, arthritis, bilirubinemia, body odor, bone disorder, bradycardia, breast pain, bronchitis, cataract, cholelithiasis, colitis, confusion, contact dermatitis, cyst, deafness, depression, dry eyes, dry mouth, dry skin, dyspnea, dysuria, ear pain, ECG abnormality, eczema, emotional lability, eructation, erythema nodosum, esophagitis, exfoliative dermatitis, eye hemorrhage, eye pain, gastritis, gastroenteritis, gastrointestinal disorder, gingivitis, glaucoma, hematuria, hepatitis, herpes simplex, hiccup, hyperkinesias, hypoesthesia, hypoglycemia, hypotension, hypothermia, insomnia, intracranial hemorrhage, laryngismus, laryngitis, leg cramps, leukopenia, liver function test abnormal, lymphadenopathy, mastitis, melena, menorrhagia, metrorrhagia, migraine, moniliasis, myasthenia, MI, neck pain, photosensitivity reaction, nervousness, ovarian disorder, pancreatitis, paresthesia, parotid gland enlargement, peripheral edema, platelet abnormality, pneumonia, pyuria, salivary gland enlargement, salpingitis, seborrhea, skin ulcer, speech disorder, sputum increased, stridor, syncope, taste loss, tendon disorder, tenosynovitis, thrombocythemia, thrombocytopenia, thrombosis, tongue disorder, twitching, urethral pain, urinary impairment, urinary urgency, vaginal hemorrhage, vaginal moniliasis, vesiculobullous rash, WBC abnormality, yawning</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505066\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to pilocarpine or any component of the formulation; uncontrolled asthma; when miosis is undesirable (eg, acute iritis, angle-closure glaucoma)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505067\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with significant cardiovascular disease; may have difficulty compensating for transient changes in hemodynamics or rhythm induced by pilocarpine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cholelithiasis: Use with caution in patients with cholelithiasis or biliary tract disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with moderate impairment; dosage adjustment recommended; use is not recommended in patients with  severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrolithiasis: Use caution in patients with a history of nephrolithiasis; may induce smooth muscle spasms, precipitating renal colic or ureteral reflux in patients with nephrolithiasis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disorders: Use with caution in patients with  controlled asthma, chronic bronchitis, or COPD; may increase airway resistance, bronchial smooth muscle tone, and bronchial secretions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505085\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2A6 (weak), CYP2E1 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505086\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9905&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May enhance the adverse/toxic effect of Cholinergic Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Cholinergic Agonists may diminish the anticholinergic effect of Cimetropium. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505095\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Fat decreases the rate of absorption, maximum concentration and increases the time it takes to reach maximum concentration. Management: Avoid administering with a high-fat meal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505064\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9887311\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20617925\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if pilocarpine is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision  be made  to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49228945\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to muscarinic (cholinergic) receptors, causing an increase in secretion of exocrine glands (such as salivary and sweat glands) and increase tone of smooth muscle in gastrointestinal and urinary tracts</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505105\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: 20 minutes; Maximum effect: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: 3 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 0.76 to 1.35 hours; mild to moderate hepatic impairment: 2.1 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: 0.85 to 1.25 hours (increased to 1.47 hours with a high-fat meal)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505266\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Pilocarpine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $161.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (100): $222.44</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Salagen Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $201.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (100): $247.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26530510\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Pilogen (BD);</li>\n      <li>Salagen (AT, BB, CH, CO, DE, ES, FI, FR, GB, GR, HK, IL, IT, JP, KR, LI, MT, PT, SE, SG, TH, TW, VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Davies AN and Singer J, &quot;A Comparison of Artificial Saliva and Pilocarpine in Radiation-Induced Xerostomia,&quot; <i>J Laryngol Otol</i>, 1994, 108(8):663-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/7930915/pubmed\" target=\"_blank\" id=\"7930915\">7930915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fox PC, Atkinson JC, Macynski AA, et al, &quot;Pilocarpine Treatment of Salivary Gland Hypofunction and Dry Mouth (Xerostomia),&quot; <i>Arch Intern Med</i>, 1991, 151(6):1149-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/2043017/pubmed\" target=\"_blank\" id=\"2043017\">2043017</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hawthorne M and Sullivan K, &quot;Pilocarpine for Radiation-Induced Xerostomia in Head and Neck Cancer,&quot; <i>Int J Palliat Nurs</i>, 2000, 6(5):228-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/12419994/pubmed\" target=\"_blank\" id=\"12419994\">12419994</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobs CD and van der Pas M, &ldquo;A Multicenter Maintenance Study of Oral Pilocarpine Tablets for Radiation-Induced Xerostomia,&rdquo; <i>Oncology</i>, 1996, 10(3 Suppl):16-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/8723429/pubmed\" target=\"_blank\" id=\"8723429\">8723429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson JT, Ferretti GA, Nethery WJ, et al, &ldquo;Oral Pilocarpine for Postirradiation Xerostomia in Patients With Head and Neck Cancer,&rdquo; <i>N Engl J Med</i>, 1993, 329(6):390-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/8326972/pubmed\" target=\"_blank\" id=\"8326972\">8326972</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LeVeque FG, Montgomery M, Potter D, et al, &ldquo;A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study of Oral Pilocarpine for Treatment of Radiation-Induced Xerostomia in Head and Neck Cancer Patients,&rdquo; <i>J Clin Oncol</i>, 1993, 11(6):1124-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/8501499/pubmed\" target=\"_blank\" id=\"8501499\">8501499</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mosqueda-Taylor A, Luna-Ortiz K, Irigoyen-Camacho ME, et al, &quot;Effect of Pilocarpine Hydrochloride on Salivary Production in Previously Irradiated Head and Neck Cancer Patients,&quot; <i>Med Oral</i>, 2004, 9(3):204-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/15122121/pubmed\" target=\"_blank\" id=\"15122121\">15122121</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson JD, Friedlaender M, Yeatts RP, et al, &quot;Oral Pilocarpine for Symptomatic Relief of Keratoconjunctivitis Sicca in Patients with Sj&ouml;gren's Syndrome. The MGI PHARMA Sj&ouml;gren's Syndrome Study Group,&quot; <i>Adv Exp Med Biol</i>, 1998, 438:979-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/9634998/pubmed\" target=\"_blank\" id=\"9634998\">9634998</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rhodus NL and Schuh MJ, &quot;Effects of Pilocarpine on Salivary Flow in Patients With Sj&ouml;gren's Syndrome,&quot; <i>Oral Surg Oral Med Oral Pathol</i>, 1991, 72(5):545-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/1745512/pubmed\" target=\"_blank\" id=\"1745512\">1745512</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rieke JW, Hafermann MD, Johnson JT, et al, &ldquo;Oral Pilocarpine for Radiation-Induced Xerostomia: Integrated Efficacy and Safety Results From Two Prospective Randomized Clinical Trials,&rdquo; <i>Int J Radiat Oncol Biol Phys</i>, 1995, 31(3):661-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/7852133/pubmed\" target=\"_blank\" id=\"7852133\">7852133</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rousseau P, &quot;Pilocarpine in Radiation-Induced Xerostomia,&quot; <i>Am J Hosp Palliat Care</i>, 1995, 12(2):38-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/7605731/pubmed\" target=\"_blank\" id=\"7605731\">7605731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Salagen (pilocarpine hydrochloride) [prescribing information]. Woodcliffe Lake, NJ: Eisai; January 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schuller DE, Stevens P, Clausen KP, et al, &ldquo;Treatment of Radiation Side Effects With Oral Pilocarpine,&rdquo; <i>J Surg Oncol</i>, 1989, 42(4):272-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/2687586/pubmed\" target=\"_blank\" id=\"2687586\">2687586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taylor SE, &quot;Efficacy and Economic Evaluation of Pilocarpine in Treating Radiation-Induced Xerostomia,&quot; <i>Expert Opin Pharmacother</i>, 2003, 4(9):1489-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/12943478/pubmed\" target=\"_blank\" id=\"12943478\">12943478</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiseman LR and Faulds D, &quot;Oral Pilocarpine: A Review of Its Pharmacological Properties and Clinical Potential in Xerostomia,&quot; <i>Drugs</i>, 1995, 49(1):143-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/7705213/pubmed\" target=\"_blank\" id=\"7705213\">7705213</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9905 Version 97.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F24521000\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9505051\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F9509745\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9505214\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F9505215\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22370241\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F9505216\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9505264\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F9505053\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9505218\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F9505054\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9505046\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9505074\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9505066\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9505067\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9505085\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9505086\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F9505095\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9505064\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9887311\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20617925\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F49228945\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F9505105\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9505266\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F26530510\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9905|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pilocarpine-systemic-patient-drug-information\" class=\"drug drug_patient\">Pilocarpine (systemic): Patient drug information</a></li></ul></div></div>","javascript":null}